GlassScriptPhysician profile
Lalit Aneja
NPI 1386989820
$17,537.78
in general payments reported to CMS, 2019-2025
76 companies · $3,337 in 2025
The $3,337 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $654 · 2021: $3,123 · 2022: $2,427 · 2023: $2,966 · 2024: $3,378 · 2025: $3,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,442 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,442.27 |
| Education | $238.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,899.61 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Epizyme, INC. | $1,301.99 | 2021-2023 | Tazverik |
| E.R. Squibb & Sons, L.L.C. | $1,207.73 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $993.27 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $879.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $877.12 | 2019-2025 | |
| Janssen Biotech, INC. | $666.77 | 2019-2025 | Tecvayli, Imbruvica, Darzalex |
| Daiichi Sankyo INC. | $633.11 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $566.33 | 2019-2025 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $536.85 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $477.55 | 2019-2025 | Polivy, Alecensa, Tecentriq |
| Lilly USA, LLC | $431.09 | 2019-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $396.11 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Gilead Sciences, INC. | $353.47 | 2019-2025 | Trodelvy |
| Seagen INC. | $351.34 | 2020-2025 | Padcev, Tukysa, Tivdak |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $334.01 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astellas Pharma US INC | $320.93 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $317.17 | 2020-2025 | |
| Genzyme Corporation | $293.15 | 2019-2025 | |
| Beigene USA, INC. | $276.33 | 2021-2025 | Brukinsa |
| Sobi, INC | $254.28 | 2023-2025 | |
| Exelixis INC. | $252.40 | 2019-2025 | Cabometyx |
| Eisai INC. | $247.36 | 2022-2025 | |
| Amgen INC. | $243.48 | 2019-2023 | Lumakras, Blincyto, Nplate |
| Regeneron Healthcare Solutions, INC. | $236.12 | 2022-2025 | Libtayo |
| Kite Pharma, INC. | $235.38 | 2020-2025 | Yescarta |
| Array Biopharma INC | $178.90 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Abbvie INC. | $166.08 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $156.80 | 2020-2025 | |
| Dendreon Pharmaceuticals LLC | $155.96 | 2022-2025 | Provenge |
| Puma Biotechnology, INC. | $150.15 | 2019-2025 | |
| Syndax Pharmaceuticals, INC. | $145.62 | 2025 | Revuforj |
| Alexion Pharmaceuticals, INC. | $121.38 | 2023-2025 | Ultomiris |
| Beone Medicines USA, INC. | $117.53 | 2025 | Brukinsa |
| Emd Serono, INC. | $105.70 | 2019-2025 | Bavencio |
| Kyowa Kirin, INC. | $105.29 | 2022-2024 | Poteligeo |
| Pharmaessentia USA Corporation | $100.78 | 2022-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $90.72 | 2019 | |
| Dova Pharmaceuticals | $85.34 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $84.75 | 2023-2025 | Orgovyx |
| Argenx US, INC. | $80.62 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Karyopharm Therapeutics INC. | $77.87 | 2022-2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $60.01 | 2023-2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $53.85 | 2022 | |
| Genmab U.S., INC. | $53.71 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.43 | 2023-2024 | Gilotrif |
| Mirati Therapeutics, INC. | $48.02 | 2024 | Krazati |
| Acrotech Biopharma INC. | $46.57 | 2022-2024 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $44.66 | 2022-2023 | Qinlock |
| Taiho Oncology, INC. | $43.29 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $41.25 | 2019-2023 | Rezlidhia, Tavalisse |
| Janssen Scientific Affairs, LLC | $41.18 | 2025 | Talvey, Carvykti, Tecvayli |
| Geron Corporation | $41.05 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $40.66 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $37.30 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $31.66 | 2025 | Zoladex |
| Immunogen, INC. | $28.08 | 2023 | Elahere |
| Myovant Sciences INC. | $27.53 | 2021 | |
| Immunocore Limited | $27.37 | 2025 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $25.84 | 2025 | Myrisk |
| Stemline Therapeutics INC. | $25.24 | 2025 | Orserdu |
| Foundation Medicine, INC. | $24.83 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $24.74 | 2025 | Onivyde |
| Heron Therapeutics, INC. | $24.62 | 2019 | |
| Morphosys, US INC. | $22.35 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $21.89 | 2025 | Ogsiveo |
| Tolmar Pharmaceuticals, INC. | $21.85 | 2022 | |
| G1 Therapeutics, INC. | $20.66 | 2023 | Cosela |
| Sun Pharmaceutical Industries INC. | $19.80 | 2024 | |
| Iovance Biotherapeutics, INC. | $19.17 | 2025 | Amtagvi |
| Ge Healthcare | $18.51 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.58 | 2023 | Epkinly, Imbruvica |
| Alnylam Pharmaceuticals INC. | $15.47 | 2025 | Givlaari |
| Cti Biopharma Corp. | $14.82 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalit Aneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.